Fundraise

Hone Health adds $28M equity in Series A extension led by Jay-Z's firm

What's the deal? Hone Health has raised $28 million in a Series A extension led by MarcyPen Capital Partners, the investment firm cofounded by Shawn "Jay-Z" Carter. The round is part of $228 million in new financing; the other $200 million comes from General Catalyst's Customer Value Fund.

What does Hone do? Founded in 2020, the online clinic began by treating men with low testosterone and has expanded into broader preventive care and women's health. It has treated about 200,000 patients across the US.

By the numbers: Hone says it surpassed $100 million in recurring revenue last year. Its January 2025 Series A raised $33 million and valued the company at $313 million.

The celebrity cap table: Other backers include Kinship VenturesDealroom has a profile for this one. Try Dealroom →, the firm Gwyneth PaltrowDealroom has a profile for this one. Try Dealroom → cofounded; Pentland VenturesDealroom has a profile for this one. Try Dealroom →; HanwhaDealroom has a profile for this one. Try Dealroom →; Gannet CapitalDealroom has a profile for this one. Try Dealroom →; and HumbitionDealroom has a profile for this one. Try Dealroom →. Individual investors span the Jonas Brothers, singer Kelly RowlandDealroom has a profile for this one. Try Dealroom →, actor Marcello Hernández, and hospitality entrepreneurs David GrutmanDealroom has a profile for this one. Try Dealroom →, Jason Strauss, and Noah Tepperberg.

Paltrow said she is also a patient. "I did all my labs and blood work and everything. I started a protocol that was incredibly helpful," she said.

How the money breaks down: Only $28 million is equity. The $200 million from General Catalyst's Customer Value Fund pays for sales and marketing and is repaid from the revenue new customers bring in — financing growth without equivalent equity dilution.

The signal: That structure is gaining traction in health and consumer businesses, with General Catalyst backing preventive-health firm FunctionDealroom has a profile for this one. Try Dealroom → and clinician-AI company Heidi the same way this year. For Hone, the test is whether it can sustain growth while delivering credible clinical outcomes.

Read more: fortune.com

Image credit: Hone Health

More top stories